TC Medical(SH:600763) Sou Hu Cai Jing·2025-08-23 22:17Core Viewpoint - Tongce Medical (600763) reported a year-on-year increase in both revenue and net profit for the first half of 2025, indicating stable growth in its financial performance [1]. Financial Performance Summary - Total revenue for the first half of 2025 reached 1.448 billion yuan, a 2.68% increase compared to 1.411 billion yuan in the same period of 2024 [1]. - Net profit attributable to shareholders was 321 million yuan, up 3.67% from 310 million yuan in the previous year [1]. - In Q2 2025, total revenue was 704 million yuan, reflecting a 0.24% increase year-on-year, while net profit for the quarter was 137 million yuan, a 0.44% increase [1]. Key Financial Ratios - Gross margin stood at 40.75%, a slight decrease of 0.20% from 40.83% [1]. - Net margin improved to 26.26%, an increase of 0.76% from 26.06% [1]. - Total expenses (selling, administrative, and financial) amounted to 175 million yuan, accounting for 12.07% of revenue, down 1.04% from the previous year [1]. Cash Flow and Debt Management - Operating cash flow per share was 0.8 yuan, a decrease of 21.66% year-on-year [1]. - The company reported a significant reduction in short-term borrowings by 37.57% due to repayment of loans [2]. - Cash flow from operating activities increased by 9.72%, attributed to higher cash receipts from sales and services [2]. Investment and Fund Holdings - The company’s return on invested capital (ROIC) was 10.81%, indicating average capital returns [2]. - The largest fund holding Tongce Medical shares is GF聚瑞混合A, with 3.3766 million shares, remaining unchanged [2].